Full-Time

Associate Director

Global Health Economics Market Access, Biosurgery

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

+ Long-term incentive program

Raritan, NJ, USA

Hybrid

The role is hybrid and based at the J&J office in Raritan, New Jersey.

Master's, MBA, PhD

Category
Growth & Marketing (1)
Required Skills
Machine Learning
Electronic Health Records (EHR)

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A certified advanced degree (Master of Science, Master of Public Health, Doctor of Philosophy, Master of Health Administration, Master of Business Administration) in a healthcare-related field; health economics, outcomes research, or a related field is required.
  • A minimum of 8–10 or more years of experience in the healthcare industry, preferably in MedTech.
  • Demonstrated acumen in developing and executing market access strategies for access to and adoption of innovative technology within the surgical procedural sector.
  • Demonstrated ability and experience working successfully in matrix environments.
  • Proven ability to understand business strategy with broad-based commercial financial acumen.
  • Strong understanding of health economics and market access analytical methods, including statistics and economic modeling, with awareness and use of emerging digital techniques such as machine learning, artificial intelligence, and intelligent automation.
  • Ability to develop strategy, execute it, and derive value creation for MedTech innovation, including developing and deploying evidence-supported claims in a dynamic organization.
  • Experience providing input to pricing strategy, building economic models and tools, and executing value-based programs such as value-based agreements throughout the product lifecycle.
  • Strong understanding of medical and surgical service delivery, technology reimbursement, market access conditions, and health policy trends in major global markets.
  • Experience leading health economic or outcomes research studies from concept through publication, including management of research vendors or consultants.
Responsibilities
  • Lead and guide global and regional cross-functional new technology innovation teams on strategic market access assessments and requirements for prioritized United States and global commercialization.
  • Partner proactively with Regional Health Economics and Market Access, Global Strategic Marketing, Clinical Research, Medical Affairs, Research and Development, and other cross-functional teams to optimize new technology innovation target product profiles.
  • Partner with regional teams to capture Health Technology Assessment strategy and execution to generate coded coverage and reimbursement aligned to Biosurgery technologies and associated procedures.
  • Lead and guide global cross-functional teams on evidentiary requirements to secure prioritized market access and payment from payers for surgeon adoption of MedTech innovation aligned to patient treatment.
  • Lead and manage research activities, including burden-of-illness research, retrospective database studies, global economic model creation, value messaging development, patient-reported outcomes development and analysis, and interpretation of economic and quality-of-life endpoints and results.
  • Collaborate with Regional Health Economics and Market Access and internal cross-functional partners to execute global economic and clinical real-world evidence generation, including retrospective payer database, electronic medical record, time-and-motion, and quality-improvement studies.
  • Lead dissemination and training on evidence generation, evidentiary analysis, and economic tools.
  • Partner with regional and local Health Economics and Market Access and commercial leaders to engage hospital administrators, surgeons, and surgical societies and identify evidence demonstrating market-specific clinical, procedural, and economic value of MedTech Biosurgery products.
  • Lead and guide development of Global Health Economics and Market Access materials and economic tool templates for regional and local teams to customize for customer-facing value propositions, value creation, adoption, and payment of Surgery products.
  • Foster a collaborative team culture and alignment with Canada, Asia-Pacific, Europe, the Middle East and Africa, and Latin America regional cross-functional and commercial teams across Surgery platforms.
Desired Qualifications
  • Global experience, with deep understanding of the United States access policy environment, external marketplace, and access requirements driving MedTech adoption.
  • Solid understanding of surgical procedures.
  • Extensive complex project and vendor management experience.
  • Strong internal and external stakeholder management skills.
  • Literacy and fluency with operating-room surgical procedure funding pathways and reimbursement mechanisms in the United States, Canada, Europe, Asia-Pacific, and Latin America.
  • Ability to travel 10–15% of the time within the domestic United States and globally.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.